Lady Davis Institute for Medical Research 

A study conducted at the Lady Davis Institute at the Jewish General Hospital revealed that pioglitazone is associated with a risk of bladder cancer that increases with duration of use and dosage.

Classified as: epidemiology, Oncology, Laurent Azoulay, Lady Davis Institute (LDI), health and lifestyle, blood sugar, pioglitazone, bladder cancer, rosiglitazone, thiazolidinediones
Published on: 31 Mar 2016
Back to top